Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05482971 · ClinicalTrials.gov registry record · Phase 2
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
A Phase 2 study of Essential Thrombocythemia, sponsored by PharmaEssentia.
- Active
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
- 20
- Study locations
NCT05482971 is a Phase 2 study of Essential Thrombocythemia that is active but no longer recruiting, run by PharmaEssentia. The registered enrollment target is 91 participants, above the 82-participant average among 16 other Essential Thrombocythemia trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT05482971, a Phase 2 study of Essential Thrombocythemia, is active but no longer recruiting, sponsored by PharmaEssentia.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essential Thrombocythemia
Conditions Studied
Interventions
- DRUG Ropeginterferon alfa-2b-njft (P1101)
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- Marin Cancer Care - Greenbrae
- USC Norris Comprehensive Cancer Center - Los Angeles
New York
- Weill Medical College of Cornell University - New York
- Memorial Sloan Kettering Cancer Center - New York
- Stony Brook University Medical Center - Stony Brook
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
New Jersey
- Astera HealthCare - East Brunswick
- John Theurer Cancer Center At Hackensack UMC - Hackensack
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Yale University School of Medicine - Yale Cancer Center - New Haven
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Georgia
- The Winship Cancer Institute Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2022-09-29 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05482971
The ClinicalTrials.gov registry entry for NCT05482971 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 82-participant average among 16 other Essential Thrombocythemia trials with a reported enrollment target (11% higher). The listed sponsor is PharmaEssentia, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Essential Thrombocythemia appearing as the primary indexed condition, and to 1 intervention - of which Ropeginterferon alfa-2b-njft (P1101) is the first listed.
NCT05482971 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, New York, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05482971 about?
NCT05482971 is a clinical study titled "A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET". A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essential Thrombocythemia
What is the current status of trial NCT05482971?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2022-09-29. Estimated completion is 2027-03-31.
What conditions does trial NCT05482971 study?
This clinical trial studies the following conditions: Essential Thrombocythemia.
What interventions are being tested in trial NCT05482971?
The interventions under investigation include: Ropeginterferon alfa-2b-njft (P1101) (DRUG).
Who is sponsoring clinical trial NCT05482971?
This trial is sponsored by PharmaEssentia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05482971 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Essential Thrombocythemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Ruxolitinib in Thrombocythemia and Polycythemia Vera
RECRUITING · Phase 2
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
-
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.